Rivastigmine for the treatment of dementia associated with Parkinson’s disease
Jennifer L Reingold, John C Morgan, Kapil D SethiMovement Disorders Program, Department of Neurology, Medical College of Georgia, Augusta, GA, USAAbstract: Parkinson’s disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of pa...
Saved in:
Main Authors: | Jennifer L Reingold, John C Morgan, Kapil D Sethi |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2007
|
Subjects: | |
Online Access: | https://doaj.org/article/b56e2e1c4a454f91ba66d014314d612c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
by: Seibert J, et al.
Published: (2012) -
Rivastigmine in Chinese patients with subcortical vascular dementia
by: Vincent Mok, et al.
Published: (2007) -
Rasagiline in treatment of Parkinson’s disease
by: Lakshmi Nayak, et al.
Published: (2008) -
Current approaches to the treatment of Parkinson’s disease
by: Joseph Jankovic, et al.
Published: (2008) -
Update on ropinirole in the treatment of Parkinson’s disease
by: Holly A Shill, et al.
Published: (2008)